| Ytd | -69.46% | |
| 1y | -21.92% |
| Open | 1.73 | Prev Close | 1.72 | Low | 1.71 | High | 1.75 | Mkt Cap | 140.55M |
| Vol | 273.86K | Avg Vol | 992.56K | EPS | -0.27 | P/E | -6.28 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-18 | 50-d Avg | 1.92 | 200-d Avg | 3.46 | 1yr Est | 0.00 |
Summary: Wall Street analysts changed rating for JAZZ, AFRM, MNDY, NGEN, FCEL, RRR, ABNB, KARO. See
HC Wainwright & Co. analyst Raghuram Selvaraju maintains NervGen Pharma (NASDAQ:NGEN) with a
Leerink Partners analyst Marc Goodman initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a O